Coronavirus vaccine being developed by Moderna shows promise in Phase 1 trial

Could be on the market as early as 2021

A Coronavirus vaccine being developed in the U.S. is on the right track so far.

That’s according to the New England Journal of Medicine, where the results of the vaccine’s “Phase-One” trial were published on Tuesday.

They showed the vaccine, developed by the biotechnology company “Moderna,”  triggered an immune response in all volunteers who received it.

On top of that-their levels of antibodies were similar to the patients who naturally recovered from COVID-19.

The 45 volunteers had only mild side effects, including fatigue, chills, and muscle pain.

The next step for the vaccine is the “Phase-Three” trial, which gets under way later this month. After that, regulators will decide whether or not to approve it.

Moderna says it will be ready to deliver up to a billion doses a year, starting in 2021.